The cost-effectiveness of tranexamic acid for treatment of postpartum hemorrhage: A systematic review.
Aziz S, Rossiter S, Homer CSE, Wilson AN, Comrie-Thomson L, Scott N, Vogel JP
Hepatitis C elimination in Myanmar: Modelling the impact, cost, cost-effectiveness and economic benefits.
Scott N, Win TM, Tidhar T, Htay H, Draper B, Aung PTZ, Xiao Y, Bowring A, Kuschel C, Shilton S, Kyi KP, Naing W, Aung KS, Hellard M
Estimating the number of new hepatitis C infections in Australia in 2015, prior to the scale-up of direct-acting antiviral treatment.
Palmer AY, Wilkinson A, Aitken C, Dietze P, Dore GJ, Maher L, Sacks-Davis R, Stoove M, Wilson D, Hellard M, Scott N
A costing analysis of a state-wide, nurse-led hepatitis C treatment model in prison.
Palmer A, Papaluca T, Stoové M, Winter R, Pedrana A, Hellard M, Wilson D, Thompson A, Scott N, EC Victoria Partnership
Authors' response to Letter to the Editor: 'Colombian experience in the management of hepatitis C'.
Schroeder S, Pedrana A, Scott N, Hellard M
Modelling the impact of reducing control measures on the COVID-19 pandemic in a low transmission setting.
Scott N, Palmer A, Delport D, Abeysuriya R, Stuart R, Kerr CC, Ministry D, Klein D, Sacks-Davis R, Heath K, Hainsworth S, Pedrana A, Stoové M, Wilson D, Hellard ME
COVID-19 Global Infectious Disease Threats Infectious Disease Modelling